41 – 50 of 164
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2014
-
Mark
188Re-ZHER2:V2, a promising affibody-based targeting agent against HER2-expressing tumors : preclinical assessment
2014) In Journal of nuclear medicine : official publication, Society of Nuclear Medicine 55(11). p.8-1842(
- Contribution to journal › Article
- 2013
-
Mark
The Intratumoral Distribution of Radiolabeled 177Lu-BR96 Monoclonal Antibodies Changes in Relation to Tumor Histology over Time in a Syngeneic Rat Colon Carcinoma Model.
(
- Contribution to journal › Article
- 2012
-
Mark
Monte Carlo Calculation in Nuclear Medicine: Applications in Diagnostic Imaging - Second Edition
Ljungberg, Michael LU ; Strand, Sven-Erik LU and King, Michael (2012)
- Book/Report › Anthology (editor)
-
Mark
Targeting Free Prostate-Specific Antigen for In Vivo Imaging of Prostate Cancer Using a Monoclonal Antibody Specific for Unique Epitopes Accessible on Free Prostate-Specific Antigen Alone.
(
- Contribution to journal › Article
-
Mark
Photon activation therapy of RG2 glioma carrying Fischer rats using stable thallium and monochromatic synchrotron radiation.
(
- Contribution to journal › Article
-
Mark
Use of Monte Carlo simulations with a realistic rat phantom for examining the correlation between hematopoietic system response and red marrow absorbed dose in Brown Norway rats undergoing radionuclide therapy with (177)Lu- and (90)Y-BR96 mAbs.
(
- Contribution to journal › Article
-
Mark
A Small-Scale Anatomic Model for Testicular Radiation Dosimetry for Radionuclides Localized in the Human Testes.
(
- Contribution to journal › Article
-
Mark
99mTc-Labeled Superparamagnetic Iron Oxide Nanoparticles for Multimodality SPECT/MRI of Sentinel Lymph Nodes.
(
- Contribution to journal › Article
-
Mark
Targeting the human kallikrein-2 (hK2) expression in prostate cancer using 111In-labelled monoclonal antibody 11B6
2012) p.1102-1102(
- Contribution to conference › Abstract
- 2011
-
Mark
Dosimetry in patients with B-cell lymphoma treated with [90Y]ibritumomab tiuxetan or [131I]tositumomab.
(
- Contribution to journal › Article